Ivan Tseng, O.D.
NPI 1083094635 · Optometrist · Ridgewood, NJ
Enrolled with Medicare as Practitioner - Optometry · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1083094635
- Entity type
- Individual
- Primary specialty
- OptometristEye and Vision Services Providers
- Credential
- O.D.
- Sex
- Male
- Sole proprietor
- No
- License
- 27OM00136800 (NJ)
Specialties & taxonomies
Eye and Vision Services Providers
Eye and Vision Services Providers
Eye and Vision Services Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
11 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
915 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Complete Exam of Visual System92014 | 257 | $144 |
| Established Patient Problem Focused Exam of Visual System92012 | 218 | $103 |
| New Patient Complete Exam of Visual System92004 | 140 | $172 |
| Imaging of Retina92134 | 92 | $45 |
| Photography of the Retina92250 | 54 | $41 |
| Exam of Visual Field With Extended Testing92083 | 40 | $71 |
| Imaging of Optic Nerve92133 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 9 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Latanoprost | 70 | 31 |
| Erythromycin Basebrand: Erythromycin | 50 | 49 |
| Neomycin/Polymyxin B/Dexamethabrand: Neomycin-Polymyxin-Dexameth | 41 | 38 |
| Lotilanerbrand: Xdemvy | 22 | 21 |
| Brimonidine Tartrate/Timololbrand: Brimonidine Tartrate-Timolol | 19 | — |
| Cyclosporinebrand: Restasis | 18 | 11 |
| Tobramycin/Dexamethasone |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$429 across 13 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2015-06-08
- Last updated
- 2022-10-19
- Certified
- 2022-10-19
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.